VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 32,083 shares, an increase of 51.1% from the July 30th total of 21,232 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average trading volume of 5,541 shares, the short-interest ratio is presently 5.8 days.

VanEck Biotech ETF Stock Up 1.4%

NASDAQ BBH opened at $242.79 on Thursday. The stock has a 50-day moving average of $215.79 and a 200 day moving average of $198.05. VanEck Biotech ETF has a twelve month low of $160.91 and a twelve month high of $244.35.

Insider Activity

In other news, major shareholder Sardar Biglari sold 2,749 shares of the firm’s stock in a transaction dated Thursday, July 16th. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30. Following the sale, the insider directly owned 3,549,961 shares in the company, valued at $59,284,348.70. This trade represents a 0.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 10,493 shares of company stock worth $175,335.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its position in shares of VanEck Biotech ETF by 40,463.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after buying an additional 492,843 shares in the last quarter. Nwam LLC purchased a new stake in VanEck Biotech ETF in the 2nd quarter worth $18,614,000. Quantitative Investment Management LLC acquired a new position in VanEck Biotech ETF during the second quarter worth $7,589,000. Ascent Advisors LLC acquired a new position in VanEck Biotech ETF during the first quarter worth $11,178,000. Finally, Raymond James Financial Inc. raised its position in VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after acquiring an additional 48,297 shares during the period. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.